Health Care • Medical/Dental Instruments
$318.95 ▼ -3.02
(-0.94%)
MKT CAP: $12.68B • VOL: 497.8K
52W L $221 52W H $362
PEN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.40B | $1.19B | $1.06B |
| YoY Revenue Growth % | +17.5% | +12.9% | — |
| Gross Profit | $942.4M | $755.0M | — |
| Gross Margin % | 67.1% | 63.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $189.2M | $9.3M | $73.6M |
| Operating Margin % | 13.5% | 0.8% | 6.9% |
| Net Income (GAAP) | $177.7M | $14.0M | $91.0M |
| EBITDA (Normalized) | $240.2M | $26.2M | $111.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $238.7M | $168.5M | $97.3M |
| Capital Expenditures (CapEx) | $63.7M | $21.2M | $47.6M |
| Free Cash Flow (FCF) | $174.9M | $147.3M | $49.7M |
| FCF Margin % | 12.5% | 12.3% | 4.7% |
| Return on Invested Capital (ROIC %) | 10.5% | 0.7% | 1.4% |
| Cash & Short-Term Equivalents | $186.9M | $324.4M | — |
| Total Debt (Short + Long Term) | $179.5M | $172.0M | $1.63B |
| Total Stockholders' Equity | $1.43B | $1.15B | $3.35B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PEN.